News
Company News: Curetis To Attend Key Investor and Scientific Conferences In The First Quarter 2018
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is going to attend several industry conferences in the first quarter of 2018.
Company News: ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. Regeneron and ISA will jointly fund and conduct clinical trials of the combination treatment in cervical cancer and head-and-neck cancer.
Company News: Provecs Medical Announces Publication of Scientific Review of Gene Therapy in Oncology
— Peer-reviewed paper in Human Gene Therapy provides comprehensive overview of using gene therapy to address multiple targets
Provecs Medical GmbH, a cancer immunotherapy company developing novel treatments to modulate the tumor microenvironment, today announced the publication of a review highlighting the use of gene therapy approaches in immuno-oncology to address multiple targets with a single drug. The paper entitled “Immuno-Oncology – the Translational Runway for Gene Therapy” will appear in the December issue of Human Gene Therapy, a peer-reviewed publication covering all aspects of human gene therapy.
Company News: Agena Bioscience´s Liquid Biopsy Technology Awarded Horizon 2020 Grant by European Union
Agena Bioscience, a global provider of molecular genetic solutions, today announced it has been selected to participate as an innovative technology provider in the ‘Liquid biopsies and IMAging for improved cancer care’ (LIMA) project.
The LIMA project has been awarded a EUR 6.3 million Horizon 2020 European Union research grant to develop an integrated approach for personalized cancer treatment. The objective of the four-year project is to develop and validate liquid biopsy technologies in the clinical workflow and to provide more precise, dynamic tumor characterization during diagnosis and treatment.